VISTAGEN THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 990.60 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 990.60K shares, a 34.85% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was -30.00K shares, a 125.48% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 188.20K shares, a 212.37% increase year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 153.25K shares, a 36.66% decline year-over-year.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2026 was 1.83M shares, a 26.54% decline from fiscal 2025.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.49M shares, a 2037.47% increase from fiscal 2024.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 116.67K shares, a 18.93% decline from fiscal 2023.
- VISTAGEN THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 143.90K shares, a 17.06% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 990.60K shares 10-Q · filed 2026-08-14 | 960.60K shares derived: sum of 2 quarters · filed 2026-08-14 | 1.15M shares derived: sum of 3 quarters · filed 2026-08-14 | 1.30M shares derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -30.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-15 | 158.20K shares derived: sum of 2 quarters · filed 2026-06-15 | 311.45K shares derived: sum of 3 quarters · filed 2026-06-15 | 1.83M shares 10-K · filed 2026-06-15 | |
| 2025-12-31 | 188.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-12 | 341.45K shares derived: sum of 2 quarters · filed 2026-02-12 | 1.86M shares 10-Q · filed 2026-02-12 | 1.98M shares derived: sum of 4 quarters · filed 2026-02-12 | |
| 2025-09-30 | 153.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-13 | 1.67M shares 10-Q · filed 2025-11-13 | 1.79M shares derived: sum of 3 quarters · filed 2025-11-13 | 1.85M shares derived: sum of 4 quarters · filed 2025-11-13 | |
| 2025-06-30 | 1.52M shares 10-Q · filed 2025-08-07 | 1.64M shares derived: sum of 2 quarters · filed 2025-08-07 | 1.70M shares derived: sum of 3 quarters · filed 2025-08-07 | 1.94M shares derived: sum of 4 quarters · filed 2025-08-07 | |
| 2025-03-31 | 117.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-17 | 178.00K shares derived: sum of 2 quarters · filed 2025-06-17 | 419.95K shares derived: sum of 3 quarters · filed 2025-06-17 | 2.49M shares 10-K · filed 2025-06-17 | |
| 2024-12-31 | 60.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | 302.20K shares derived: sum of 2 quarters · filed 2025-02-13 | 2.38M shares 10-Q · filed 2025-02-13 | ||
| 2024-09-30 | 241.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | 2.32M shares 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | 2.07M shares 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | 116.67K shares 10-K · filed 2024-06-11 | ||||
| 2023-03-31 | 143.90K shares 10-K · filed 2023-06-28 | ||||
| 2022-03-31 | 173.50K shares 10-K · filed 2023-06-28 | 5.21M shares 10-K · filed 2022-06-23 | |||
| 2021-03-31 | 4.99M shares 10-K · filed 2022-06-23 | ||||
| 2020-03-31 | 3.46M shares 10-K · filed 2021-06-29 | ||||
| 2019-03-31 | 1.35M shares 10-K · filed 2020-06-29 | ||||
| 2018-03-31 | 3.67M shares 10-K · filed 2019-06-25 | ||||
| 2017-09-30 | 770.00K shares 10-Q · filed 2018-02-12 | ||||
| 2017-03-31 | 1.34M shares 10-K · filed 2018-06-26 | ||||
| 2016-09-30 | 125.00K shares 10-Q · filed 2018-02-12 | ||||
| 2016-03-31 | 145.00K shares 10-K · filed 2017-06-29 | ||||
| 2014-09-30 | -76.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-11-19 | 4.00K shares 10-Q · filed 2014-11-19 | |||
| 2014-06-30 | 80.00K shares 10-Q · filed 2014-08-12 | ||||
| 2013-12-31 | 76.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-02-17 | 76.00K shares derived: sum of 2 quarters · filed 2015-02-17 | 156.00K shares 10-Q · filed 2015-02-17 | ||
| 2013-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-11-14 | 80.00K shares 10-Q · filed 2013-11-14 | |||
| 2013-06-30 | 80.00K shares 10-Q · filed 2013-08-14 | ||||
| 2012-09-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-11-14 | 155.00K shares 10-Q · filed 2013-11-14 | |||
| 2012-06-30 | 155.00K shares 10-Q · filed 2013-08-14 | ||||
| 2011-09-30 | -570.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2012-11-14 | 230.00K shares 10-Q · filed 2012-11-14 | |||
| 2011-06-30 | 800.00K shares 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |